Ohio Lottery Incentive Program Shows No Associated Increase In COVID-19 Vaccination Rates
July 7th 2021The study evaluated vaccination trends among adults aged 18 years or older using data from the CDC, comparing the rates in Ohio before and after the implementation of the lottery with states that did not have lottery programs.
Read More
Pharmacy Focus Podcast: Women in Pharmacy Wednesday- Episode 3
July 7th 2021The Pharmacy Times® Pharmacy Focus podcast provides the latest industry news and information, thought-leader insights, clinical updates, patient counseling tools, and innovative solutions for the everyday practice and business of pharmacy.
Listen
Michael Radin, MD, executive director, Diabetes Cardio Renal Medical Director Team, Medical Affairs, Novo Nordisk, discusses how the results from the phase 3 trial evaluating an investigational 2 mg dose of semaglutide could change treatment options for patients with type 2 diabetes.
Watch
Milind Javle, PhD, professor of Gastrointestinal Medical Oncology at the University of Texas MD Anderson Cancer Center, discussed the dosing and treatment cycle during the trial assessing infigratinib for the treatment of previously treated locally advanced or metastatic cholangiocarcinoma.
Watch
Assessing the Use of Dapagliflozin in Patients With Type 2 Diabetes Hospitalized With COVID-19
July 5th 2021Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, discussed how the phase 3 DARE-19 trial was conducted to assess dapagliflozin in patients with type 2 diabetes hospitalized with COVID-19.
Watch
Safety Profile of Dapagliflozin Among Patients With Type 2 Diabetes Hospitalized With COVID-19
July 2nd 2021Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, discussed the findings around the safety profile of dapagliflozin in patients with and without type 2 diabetes hospitalized with COVID-19 during the DARE-19 trial.
Watch
Assessing Adverse Events From Investigational Dose of Semaglutide Injection for Type 2 Diabetes
July 2nd 2021Michael Radin, MD, executive director, Diabetes Cardio Renal Medical Director Team, Medical Affairs, Novo Nordisk, discusses the adverse events experienced by patients during the SUSTAIN FORTE phase 3 clinical trial evaluating an investigational 2 mg dose of semaglutide injection in adults with type 2 diabetes.
Watch